Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 909-917

  Lohse, Nicolai ^a,b   Jørgensen, Louise B ^c   Kronborg, Gitte ^d   Møller, Axel ^e   Kvinesdal, Birgit ^f   Sørensen, Henrik T ^a,g   Obel, Niels ^b,h   Gerstoft, Jan ^b   Gerstat, J ^b   Obel, N ^b   Kronborg, G ^b   Pedersen, C ^h   Larsen, C S ^a   Pedersen, G ^a   Laursen, A L ⁱ   Kvinesdal, B ^j   Moller A ^k  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet

^c STATENS SERUM INSTITUT   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e KOLDING HOSPITAL   (Denmark)

^f Nordsjællands Hospital Hillerød   (Denmark)

^g BOSTON UNIVERSITY   (United States)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ HERNING HOSPITAL   (Denmark)

^j Helsinger Hospital

^k Kolding Hospital

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT FAILURE; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; TREATMENT FAILURE;

EID: 34848922187     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS 2005; 19:815-822.
2. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 2004; 190:1947-1956.
3. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
4. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40:34-40.
5. Recsky MA, Brumme ZL, Chan KJ, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004; 190:285-292.
6. Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19:1081-1089.
7. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004; 18:1539-1548.
8. Lohse N, Hansen AB, Jensen-Fangel S, et al. Demographics of HIV-1 infection in Denmark: Results from The Danish HIV Cohort Study. Scand J Infect Dis 2005; 37:338-343.
9. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131.
10. Pedersen CB, Gøtzsche H, Møller JØ, Mortensen PB. The Danish Civil Registration System. Dan Med Bull 2006; 53:441-449.
11. Brun-Vezinet F, Costagliola D, Khaled MA, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004; 9:465-478.
12. Flandre P, Descamps D, Joly V, et al. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received. Antivir Ther 2003; 8:65-72.
13. Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10:791-802.
14. Marcelin AG, Delaugerre C, Wirden M, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.
15. De Luca A, Di Giambenedetto S, Romano L, et al. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006; 193:1219-1222.
16. Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 2006; 80:7020-7027.
17. + cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 2003; 139:810-816.
18. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183.
19. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17:1925-1932.
20. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
21. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904-911.
22. Wu TD, Schiffer CA, Gonzales MJ, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003; 77:4836-4847.
23. Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavirritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2004; 48:4687-4692.
24. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother 2005; 55:413-416.
25. Machouf N, Thomas R, Nguyen VK, et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 2006; 78:608-613.
26. Jorgensen LB, Christensen MB, Gerstoft J, et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 2003; 35:800-807.
27. Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 2006; 11:591-600.
28. Hogg R, Bangsberg D, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:1570-1578.